Analyst Consensus ?
ConsensusBuy45 ratings
Bullish2862.2%
Neutral1533.3%
Bearish24.5%
FN2 Earnings Intelligence
HCA Healthcare, Inc. complete analyst coverage
HCA Healthcare, Inc. (HCA) analyst consensus, price targets, and firm-level rating history from FN2 Research.
Analyst 52W Price Targets
$418.19Previous close
$224Low
$396.95Average
$579High
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Jul 29, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Barclays | Equal Weight | Equal Weight | Maintain | Jul 27, 2026 |
| Baird | Neutral | Neutral | Maintain | Jul 27, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Jul 15, 2026 |
| Keybanc | Overweight | Overweight | Maintain | Jul 14, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Jul 13, 2026 |
| Cantor Fitzgerald | Overweight | Overweight | Maintain | Jul 7, 2026 |
| TD Cowen | Buy | Buy | Maintain | Jun 22, 2026 |
| Bernstein | Market Perform | Market Perform | Maintain | Jun 4, 2026 |
| Truist Securities | Buy | Buy | Maintain | Apr 27, 2026 |
| Stephens & Co. | Overweight | Overweight | Maintain | Apr 27, 2026 |
| Oppenheimer | Outperform | Outperform | Maintain | Apr 27, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Feb 25, 2026 |
| UBS | Buy | Buy | Maintain | Feb 23, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Feb 20, 2026 |
| Argus Research | Buy | Buy | Maintain | Feb 6, 2026 |
| Jefferies | Buy | Buy | Maintain | Jan 28, 2026 |
| Deutsche Bank | Buy | Buy | Maintain | Jan 28, 2026 |
| Morgan Stanley | Underweight | Equal Weight | Downgrade | Dec 15, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | Oct 27, 2025 |
| B of A Securities | Neutral | Neutral | Maintain | Oct 27, 2025 |
| Wolfe Research | Peer Perform | Outperform | Downgrade | Jul 28, 2025 |
| Raymond James | Market Perform | Outperform | Downgrade | Nov 22, 2024 |
| Leerink Partners | Outperform | Outperform | Maintain | Jul 24, 2024 |
| Citigroup | Buy | Buy | Maintain | Oct 25, 2023 |
| Credit Suisse | Outperform | Outperform | Maintain | Jul 28, 2023 |
| Loop Capital | Buy | Buy | Maintain | Apr 24, 2023 |
| Cowen & Co. | Outperform | Outperform | Maintain | Jan 30, 2023 |
| SVB Leerink | Outperform | Outperform | Maintain | Dec 16, 2022 |
| BMO Capital | Underperform | Market Perform | Downgrade | Jul 6, 2022 |
| Seaport Global | Buy | Buy | Maintain | Jul 9, 2021 |
| Piper Sandler | Neutral | Neutral | Maintain | Nov 25, 2020 |
| SunTrust Robinson Humphrey | Buy | Buy | Maintain | Apr 22, 2020 |
| Bank of America | Buy | Neutral | Upgrade | Dec 6, 2019 |
| Argus | Buy | Buy | Maintain | Nov 6, 2018 |
| Leerink Swann | Outperform | Outperform | Maintain | Sep 4, 2018 |
| PiperJaffray | Neutral | Overweight | Downgrade | Jan 3, 2018 |
| William Blair | Perform | Market Perform | Maintain | Nov 21, 2017 |
| Avondale Partners | Market Perform | Market Outperform | Downgrade | Nov 9, 2016 |
| Evercore ISI Group | Hold | Hold | Maintain | Sep 23, 2016 |
| Longbow Research | Market Perform | Outperform | Downgrade | Jan 6, 2016 |
| Wedbush | Outperform | Outperform | Maintain | Jun 10, 2015 |
| Sterne Agee | Buy | Buy | Maintain | Dec 18, 2014 |
| Monness Crespi Hardt | Buy | Buy | Maintain | Mar 31, 2014 |
| Macquarie | Neutral | Outperform | Downgrade | Mar 12, 2013 |
| Imperial Capital | Outperform | Outperform | Maintain | Jan 17, 2013 |
Named analyst price targets
Upside is calculated against the persisted previous close $418.19. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Goldman Sachs | Analyst unavailable | $485 | $389.62 | +16.0% | Jul 28, 2026 |
| UBS | Analyst unavailable | $579 | $390.7 | +38.5% | Jul 27, 2026 |
| Deutsche Bank | Analyst unavailable | $476 | $387.41 | +13.8% | Jul 27, 2026 |
| Morgan Stanley | Analyst unavailable | $380 | $388.48 | -9.1% | Jul 27, 2026 |
| Oppenheimer | Michael Wiederhorn | $485 | $388.93 | +16.0% | Jul 27, 2026 |
| Robert W. Baird | Analyst unavailable | $393 | $382.19 | -6.0% | Jul 27, 2026 |
| Barclays | Analyst unavailable | $387 | $382.19 | -7.5% | Jul 27, 2026 |
| KeyBanc | Analyst unavailable | $435 | $382.19 | +4.0% | Jul 27, 2026 |
| Wells Fargo | Stephen Baxter | $369 | $371.18 | -11.8% | Jul 20, 2026 |
| Barclays | Analyst unavailable | $402 | $378.85 | -3.9% | Jul 16, 2026 |
| RBC Capital | Analyst unavailable | $435 | $363.6 | +4.0% | Jul 15, 2026 |
| Jefferies | Analyst unavailable | $450 | $363.6 | +7.6% | Jul 14, 2026 |
| Wells Fargo | Analyst unavailable | $428 | $406.59 | +2.3% | Jul 13, 2026 |
| Barclays | Analyst unavailable | $427 | $423.11 | +2.1% | Jul 8, 2026 |
| Raymond James | Sarah James | $528 | $424.8 | +26.3% | Jul 7, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $525 | $417.07 | +25.5% | Jul 7, 2026 |
| Truist Financial | Analyst unavailable | $413 | $367.69 | -1.2% | Jun 4, 2026 |
| Bernstein | Analyst unavailable | $413 | $363.23 | -1.2% | Jun 4, 2026 |
| Stephens | Analyst unavailable | $530 | $444.76 | +26.7% | Apr 27, 2026 |
| Truist Financial | Analyst unavailable | $535 | $432.46 | +27.9% | Apr 27, 2026 |
| Oppenheimer | Analyst unavailable | $520 | $432.46 | +24.3% | Apr 27, 2026 |
| RBC Capital | Analyst unavailable | $534 | $432.46 | +27.7% | Apr 27, 2026 |
| Wells Fargo | Analyst unavailable | $436 | $432.46 | +4.3% | Apr 27, 2026 |
| KeyBanc | Analyst unavailable | $510 | $432.46 | +22.0% | Apr 27, 2026 |
| Barclays | Analyst unavailable | $496 | $432.46 | +18.6% | Apr 27, 2026 |
| Jefferies | Analyst unavailable | $525 | $432.46 | +25.5% | Apr 24, 2026 |
| UBS | Analyst unavailable | $635 | $532.3 | +51.8% | Feb 23, 2026 |
| Bernstein | Analyst unavailable | $541 | $501.69 | +29.4% | Feb 9, 2026 |
| Mizuho Securities | Analyst unavailable | $540 | $488.27 | +29.1% | Feb 2, 2026 |
| Wells Fargo | Analyst unavailable | $481 | $482.53 | +15.0% | Jan 30, 2026 |
| RBC Capital | Analyst unavailable | $555 | $483.16 | +32.7% | Jan 28, 2026 |
| KeyBanc | Analyst unavailable | $503 | $483.76 | +20.3% | Jan 28, 2026 |
| UBS | Analyst unavailable | $598 | $487.53 | +43.0% | Jan 28, 2026 |
| Oppenheimer | Analyst unavailable | $540 | $505.84 | +29.1% | Jan 28, 2026 |
| UBS | Analyst unavailable | $588 | $505.84 | +40.6% | Jan 28, 2026 |
| KeyBanc | Analyst unavailable | $550 | $505.84 | +31.5% | Jan 28, 2026 |
| Barclays | Andrew Mok | $551 | $505.84 | +31.8% | Jan 28, 2026 |
| KeyBanc | Analyst unavailable | $500 | $465.44 | +19.6% | Jan 22, 2026 |
| Wells Fargo | Stephen Baxter | $452 | $483.6 | +8.1% | Jan 7, 2026 |
| Bernstein | Analyst unavailable | $503 | $479.53 | +20.3% | Jan 6, 2026 |
| Mizuho Securities | Analyst unavailable | $520 | $471.85 | +24.3% | Dec 18, 2025 |
| Truist Financial | Analyst unavailable | $495 | $447.04 | +18.4% | Oct 27, 2025 |
| Stephens | Raj Kumar | $500 | $447.04 | +19.6% | Oct 27, 2025 |
| RBC Capital | Ben Hendrix | $482 | $447.04 | +15.3% | Oct 27, 2025 |
| Barclays | Analyst unavailable | $494 | $454.84 | +18.1% | Oct 27, 2025 |
| UBS | Analyst unavailable | $525 | $454.84 | +25.5% | Oct 27, 2025 |
| Morgan Stanley | Analyst unavailable | $425 | $452.07 | +1.6% | Oct 27, 2025 |
| Goldman Sachs | Scott Fidel | $520 | $452.23 | +24.3% | Oct 27, 2025 |
| Raymond James | Sarah James | $525 | $454.58 | +25.5% | Oct 27, 2025 |
| Oppenheimer | Analyst unavailable | $500 | $454.03 | +19.6% | Oct 27, 2025 |
| Mizuho Securities | Analyst unavailable | $505 | $453.92 | +20.8% | Oct 27, 2025 |
| Bernstein | Analyst unavailable | $417 | $451.02 | -0.3% | Oct 27, 2025 |
| Mizuho Securities | Analyst unavailable | $475 | $419.6 | +13.6% | Oct 17, 2025 |
| Truist Financial | Analyst unavailable | $460 | $412.66 | +10.0% | Oct 14, 2025 |
| UBS | Analyst unavailable | $495 | $415.65 | +18.4% | Oct 14, 2025 |
| Goldman Sachs | Analyst unavailable | $470 | $410.68 | +12.4% | Oct 14, 2025 |
| UBS | Analyst unavailable | $465 | $437.57 | +11.2% | Oct 8, 2025 |
| Wells Fargo | Analyst unavailable | $412 | $433.55 | -1.5% | Oct 7, 2025 |
| Barclays | Analyst unavailable | $445 | $401.1 | +6.4% | Sep 18, 2025 |
| RBC Capital | Ben Hendrix | $401 | $334.29 | -4.1% | Jul 28, 2025 |
| Morgan Stanley | Craig Hettenbach | $410 | $373.01 | -2.0% | Jun 9, 2025 |
| Barclays | Andrew Mok | $416 | $382.16 | -0.5% | Jun 2, 2025 |
| KeyBanc | Matthew Gillmor | $370 | $308.21 | -11.5% | Jan 7, 2025 |
| Oppenheimer | Michael Wiederhorn | $400 | $359.07 | -4.3% | Oct 28, 2024 |
| KeyBanc | Matthew Gillmor | $420 | $359.07 | +0.4% | Oct 28, 2024 |
| Mizuho Securities | Ann Hynes | $425 | $359.16 | +1.6% | Oct 28, 2024 |
| KeyBanc | Matthew Gillmor | $475 | $387.25 | +13.6% | Oct 10, 2024 |
| Deutsche Bank | Pito Chickering | $441 | $406.01 | +5.5% | Oct 1, 2024 |
| Truist Financial | David MacDonald | $430 | $373.77 | +2.8% | Aug 19, 2024 |
| Deutsche Bank | Pito Chickering | $375 | $335.04 | -10.3% | Jun 28, 2024 |
| Jefferies | Brian Tanquilut | $390 | $336.82 | -6.7% | Jun 6, 2024 |
| RBC Capital | Ben Hendrix | $329 | $311.07 | -21.3% | Apr 29, 2024 |
| Oppenheimer | Michael Wiederhorn | $345 | $306.69 | -17.5% | Apr 29, 2024 |
| Deutsche Bank | Pito Chickering | $359 | $327.25 | -14.2% | Apr 12, 2024 |
| Oppenheimer | Michael Wiederhorn | $310 | $285.91 | -25.9% | Apr 24, 2023 |
| Goldman Sachs | Analyst unavailable | $296 | $257.09 | -29.2% | Feb 8, 2023 |
| UBS | Analyst unavailable | $296 | $257.85 | -29.2% | Jan 13, 2023 |
| Wells Fargo | Analyst unavailable | $243 | $243.21 | -41.9% | Jan 3, 2023 |
| Leerink Partners | Analyst unavailable | $286 | $239.7 | -31.6% | Dec 16, 2022 |
| Goldman Sachs | Analyst unavailable | $265 | $241.35 | -36.6% | Dec 12, 2022 |
| Raymond James | Analyst unavailable | $250 | $208.97 | -40.2% | Sep 16, 2022 |
| Leerink Partners | Analyst unavailable | $259 | $210.25 | -38.1% | Aug 24, 2022 |
| Mizuho Securities | Ann Hynes | $230 | $213.47 | -45.0% | Aug 16, 2022 |
| Wells Fargo | Analyst unavailable | $199 | $204.66 | -52.4% | Jul 28, 2022 |
| Raymond James | Analyst unavailable | $230 | $198.63 | -45.0% | Jul 26, 2022 |
| RBC Capital | Analyst unavailable | $249 | $198.53 | -40.5% | Jul 25, 2022 |
| Credit Suisse | Analyst unavailable | $250 | $202.87 | -40.2% | Jul 25, 2022 |
| Truist Financial | Analyst unavailable | $240 | $202.03 | -42.6% | Jul 25, 2022 |
| Leerink Partners | Analyst unavailable | $240 | $202.03 | -42.6% | Jul 25, 2022 |
| Leerink Partners | Analyst unavailable | $212 | $167.49 | -49.3% | Jul 15, 2022 |
| Goldman Sachs | Analyst unavailable | $233 | $170.02 | -44.3% | Jul 12, 2022 |
| Raymond James | Analyst unavailable | $220 | $172.6 | -47.4% | Jul 11, 2022 |
| Deutsche Bank | Analyst unavailable | $200 | $172.76 | -52.2% | Jul 7, 2022 |
| Mizuho Securities | Analyst unavailable | $210 | $168.06 | -49.8% | Jul 1, 2022 |
| RBC Capital | Analyst unavailable | $256 | $173.1 | -38.8% | Jun 21, 2022 |
| Loop Capital Markets | Joseph France | $240 | $171.56 | -42.6% | Jun 16, 2022 |
| Mizuho Securities | Analyst unavailable | $260 | $215.7 | -37.8% | May 3, 2022 |
| BMO Capital | Matt Borsch | $240 | $219.06 | -42.6% | Apr 28, 2022 |
| UBS | Analyst unavailable | $241 | $210.9 | -42.4% | Apr 26, 2022 |
| Raymond James | Analyst unavailable | $245 | $210.5 | -41.4% | Apr 26, 2022 |
| Truist Financial | Analyst unavailable | $250 | $210.56 | -40.2% | Apr 25, 2022 |
| Wells Fargo | Analyst unavailable | $227 | $211.94 | -45.7% | Apr 25, 2022 |
| Credit Suisse | Analyst unavailable | $260 | $208.7 | -37.8% | Apr 25, 2022 |
| Leerink Partners | Analyst unavailable | $273 | $210.64 | -34.7% | Apr 25, 2022 |
| Citigroup | Analyst unavailable | $254 | $210.64 | -39.3% | Apr 25, 2022 |
| RBC Capital | Analyst unavailable | $267 | $210.64 | -36.2% | Apr 25, 2022 |
| Wells Fargo | Steve Baxter | $227 | $210.5 | -45.7% | Apr 25, 2022 |
| Barclays | Sarah James | $256 | $210.64 | -38.8% | Apr 22, 2022 |
| Mizuho Securities | Ann Hynes | $290 | $210.64 | -30.7% | Apr 22, 2022 |
| Truist Financial | David S Macdonald | $310 | $258.43 | -25.9% | Jan 5, 2022 |
| Jefferies | Brian Tanquilut | $310 | $259.72 | -25.9% | Jan 4, 2022 |
| J.P. Morgan | Lisa Gill | $270 | $246.51 | -35.4% | Dec 21, 2021 |
| Mizuho Securities | Ann Hynes | $290 | $245.1 | -30.7% | Dec 20, 2021 |
| Raymond James | John Ransom | $300 | $240.42 | -28.3% | Oct 26, 2021 |
| Oppenheimer | Michael Wiederhorn | $290 | $240.83 | -30.7% | Oct 25, 2021 |
| Deutsche Bank | Pito Chickering | $306 | $240.83 | -26.8% | Oct 25, 2021 |
| Barclays | Sarah James | $275 | $244.85 | -34.2% | Aug 16, 2021 |
| Argus Research | Jasper Hellweg | $275 | $249.51 | -34.2% | Aug 2, 2021 |
| Wolfe Research | Justin Lake | $224 | $206.85 | -46.4% | Jun 21, 2021 |
Track every rating change on HCA the moment it posts. Free to start.
Start free